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Chemistry
General information
All chemicals were purchased from commercial suppliers: Activate Scientific, Sigma-
Aldrich, TCI, Thermo Fisher Scientific, and Alfa Aesar and used as received unless 
otherwise specified. For all reactions, analytical grade solvents were used. All 
moisture- sensitive reactions were carried out in oven-dried glassware (135°C). 
Microwave reactions were performed in a Microwave Biotage Initiator+ with a Robot 
Sixty autosampler. For structural elucidation 1H-, 13C-, 13C apt- ,19F-, HMQC-, 
HMBC-, NOESY- and ROESY-spectra were recorded. The latter two, as well as a 1H-
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spectrum with long relaxation time were measured on a cryometer head. All 
measurements, except 19F-NMR and 13C apt-NMR spectroscopy were performed on 
the AV 600 instrument. All 13C-NMR measurements were performed proton 
decoupled. The signal of the respective deuterated solvent (DMSO, CDCl3, CD3CN) 
was used as a reference for the internal shift. For the 19F-NMR measurements, TMS 
was used as a signal reference. Abbreviations used are: s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, br. s = broad singlet. Coupling constants (J) are 
expressed in Hz. NMR data were analyzed with MestReNova software. Mass spectra 
were obtained with two different spectrometers using the same column. LCMS 
(method 1): instrument: Agilent Technologies 6220 Accurate Mass TOF LC/MS linked 
to Agilent Technologies HPLC 1200 Series; column: Thermo Accuore RP-MS; 
particle size: 2.6 μM dimension: 30 × 2.1 mm; Eluent A: H2O with 0.1% formic acid 
(FA) Eluent B: MeCN with 0.1% FA; gradient: 0.00 min 95% A, 0.2 min 95% A, 1.1 
min 1% A, 2.5 min Stoptime, 1.3 min Posttime; flow rate: 0.8 ml min−1; UV-detection: 
220 nm, 254 nm, 300 nm. LCMS (method 2): instrument: Agilent Technologies 6120 
Quadrupole LC/MS linked to Agilent HPLC 1290 Infinity; column: Thermo Accuore 
RP-MS; particle size: 2.6 μM dimension: 30 × 2.1 mm; Eluent A: H2O with 0.1% FA 
Eluent B: MeCN with 0.1% FA; gradient: 0.00 min 95% A, 0.2 min 95% A, 1.1 min 1% 
A, 2.5 min Stoptime, 1.3 min Posttime; flow rate: 0.8 ml/min; UV-detection: 220 nm, 
254 nm, 300 nm. Percolated aluminum sheets (Merck Silica gel/TLC-cards, 254 nm) 
were used for TLC. Purification of the compounds was either performed by flash 
chromatography using an Isolera System from Biotage or by reversed HPLC using a 










4-(Trifluoromethoxy)aniline (133 mg, 0.75 mmol) was dissolved with NaHCO3 (47.1 
mg, 0.55 mmol) in distilled water (0.4 mL) and heated to 50°C. 5-Methyl-4-isoxazolic 
acid chloride (383 mg, 2.6 mmol) was added slowly, and a colourless solid 
precipitated immediately. The solution was decanted, the residue was washed with 
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distilled water (2 x 8 mL) and then dried in high vacuum to yield the product as a 
colorless amorphous solid (197 mg, 92%). 1H-NMR (600 MHz, Chloroform-d) 
δ = 8.46 (s, 1H, H3), 7.59 (d, 3JHH = 8.6 Hz, 2H, H11; H14), 7.47 (s, 1H, H8) 7.22 (d, 
3JHH = 8.5 Hz, 2H, H10, H14), 2.77 (s, 3H, H16). 13C-NMR (151 MHz, Chloroform-d) 
δ = 173.8 (s, C1), 159.2 (s, C6), 147.4 (s, C3), 145.9 (s, C12), 135.7 (s, C9), 121.9 
(s, 2C, C10; C14), 121.7 (s, 2C, C11; C13), 120.4 (q, 1JCF = 257.1 Hz, 1C, C17), 
111.7(s, C2) , 12.6 (s, C16). 19F-NMR (282 MHz, Chloroform-d) δ = 19.4. LCMS (pos. 
ESI) m/z: [M+H]+ (calcd) for C12H10F3N2O3 = 287.0638; found: 287.0. HRMS (ESI) 









5-Methyl-N-(4-(trifluoromethoxy)-phenyl)isoxazole-4-carboxamide (41.1 mg, 0.14 
mmol) was dissolved in ethyl acetate (0.12 mL), mixed with 0.07 mL aqueous NaOH 
(8.0 mg, 0.20 mmol,) and methanol (0.08 mL) and heated to 55°C for 1h. After 
cooling to 30°C, distilled water (0.2 mL) and subsequently 2N HCl solution (0.11 mL) 
was added and stirred for 1 h. The suspension was brought to room temperature, the 
solvent was decanted, the pink solid was washed three times with distilled water (9 
mL) and dried in high vacuum to yield an amorphous solid (24.3 mg, 59%).1H-NMR 
(600 MHz, DMSO-d6) δ = 10.68 (s, 1H, H8), 9.92 (s, 1H, H8 (I)), 7.69 (d, 3JHH = 8.7 
Hz, 2H, H11; H16 (I)), 7.64 (d, 3JHH = 9.0 Hz, 2H, H11; H16), 7.31 (d, 3JHH = 8.7 Hz, 
2H, H12; H15), 2.36 (s, 3H, H8 (I)), 2.25 (s, 3H, H8). 13C-NMR (151 MHz, DMSO-d6) 
δ = 187.9 (s, C6), 167.1 (s, C2), 144.6 (s, C13), 137.5 (s, C10), 123.2 (s, 2C, C12; 
C15), 121.9 (s, 2C, C11; C16), 120.6 (q, 1JFF = 255.7 Hz, 1C, C17), 80.5 (s, C3), 23.7 
(s, C8). 19F-NMR (282 MHz, DMSO-d6) δ = 20.5. LCMS (pos. ESI) m/z: [M+H]+ 
(calcd) for C12H10F3N2O3 = 287.0638; found: 287.0. HRMS (ESI) m/z: [M - H]- calcd 
for C12H9F3N2O3 = 286.0565, found: 286.0575.










3,5-Bis(trifluoromethyl)aniline (217.6 mg, 0.95 mmol) was suspended with NaHCO3 
(62 mg, 0.74 mmol) in distilled water (0.4 mL) and heated to 50°C. 5-Methyl-4-
isoxazolic acid chloride (158.4 mg, 1.09 mmol) was added over 5 minutes, resulting 
in precipitation of a colourless solid. After 20 min the reaction was brought to room 
temperature, the solvent was decanted and the residue was washed with 1N HCl 
solution (2 x 10 mL) and distilled water (10 mL). The product was dried in a high 
vacuum and isolated as colorless amorphous solid (305 mg, 95%). 1H-NMR (600 
MHz, DMSO-d6) δ = 10.58 (s, 1H, H8), 9.06 (s, 1H, H3), 8.39 (s, 2H, H10; H14), 7.83 
(s, 1H, H12), 2.71 (s, 3H, H15). 13C-NMR (151 MHz, DMSO-d6) δ = 174.3 (s, C1), 
160.3 (s, C6), 149.3 (s, C3), 141.0 (s, C9), 131.2 (q, 2JCF = 32.8 Hz, 2C, C11; C13), 
123.7 (q, 1JCF = 272.7 Hz, 2C, C16; C20), 120.2 (s, 2C, C10; C14), 117.1 (s, C12), 
111.9 (s, C2), 12.7 (s, C15). 19F -NMR (282 MHz, Chloroform-d) δ = 14.5. LCMS 
(pos. ESI) m/z: [M+H]+ (calcd) for C13H9F6N2O2 = 339.0563; found: 339.1. HRMS 








N-(3,5-Bis(trifluoromethyl)phenyl)- 5-methylisoxazole-4-carboxamide (68.4 mg, 0.2 
mmol) was placed in ethyl acetate (0.23 mL), mixed with 0.01 mL aqueous NaOH 
(11.3 mg, 0.28 mmol) and methanol (0.11 mL) and heated to 55°C for 1h. Then 
distilled water (0.34 mL) and 2N HCl solution (0.2 mL) was added at 30°C and the 
mixture was stirred for 1 h at 25°C. The solvent was decanted and the product was 
washed with distilled water (3 x 9 mL) and dried in a high vacuum to yield a slightly 
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pink amorphous solid (41 mg, 60%). 1H-NMR (600 MHz, DMSO-d6) δ = 11.54 (s, 1H, 
H9), 10.29 (s, 1H, H9 (I)), 8.34 (s, 2H, H11, H15 (I)), 8.25 (s, 2H, H11, H15), 7.75 (s, 
1H, H13 (I)), 7.68 (s, 1H, H13), 2.42 (s, 1H, H8 (I)), 2.21 (s, 3H, H8). 13C-NMR (151 
MHz, DMSO-d6) δ = 188.1 (s, C6), 167.1 (s, C2), 141.3 (s, C10), 131.0 (q, 2JFF = 32.6 
Hz, 2C, C12; C14), 123.7 (q, 2JFF = 272.8 Hz, 2C, C16; C20), 120.5 (s, C4), 120.4 (s, 
2C, C11; C15), 115.9 (s, C13), 80.1 (s, C13), 24.9 (s, C8). 19F NMR (282 MHz, 
DMSO-d6) δ = 15.9 (s, 6F, F17-19; F21-23), 15.9 (s, 6F, F17-19; F21-23(I)). LCMS 
(pos. ESI) m/z: [M+H]+ (calcd) for C13H9F6N2O2 = 339.0563; found: 339.0.  HRMS 















4-(Pentafluorothio)aniline (142.6 mg, 0.65 mmol) was dissolved with NaHCO3 (61.9 
mg, 0.74 mmol) in distilled water (0.4 mL) with toluene (0.05 mL) and heated to 50°C. 
5-Methyl-4-isoxazolic acid chloride (114.4 mg, 0.78 mmol) was added over 5 
minutes, resulting in a colorless solid. After 20 min, the reaction was brought to room 
temperature, the solvent was decanted and the residue treated with 1N HCl solution 
(2 x 10 mL) and washed with distilled water (10 mL). The product was dried in a high 
vacuum and was isolated as a colorless solid (201 mg, 79%). 1H-NMR (600 MHz, 
DMSO-d6) δ = 10.41 (s, 1H, H8), 9.09 (s, 1H, H3), 7.94 – 7.88 (m, 4H, H10; H14; 
H11; H13), 2.69 (s, 3H, H21). 13C-NMR (151 MHz, DMSO-d6) δ = 174.0 (s, C1), 
160.1 (s, C6), 149.5 (s, C3), 148.4 – 147.8 (m, 1C, C12), 142.4 (s, C9), 127.2 (s, 2C, 
C11; C13), 120.2 (s, 2C, C10, C14), 112.1 (s, C2), 12.7 (s, C21). 19F-NMR (282 MHz, 
DMSO-d6) δ = 166.1 (p, 2JFF = 149.3 Hz, 1F, F19), 142.4 (d, 2JFF = 151.0 Hz, 4F, 
F16; F17; F18; F20). LCMS (pos. ESI) m/z: [M+H]+ (calcd) for 
C11H10F5N2O2S = 329.0378; found: 329.0. HRMS (ESI) m/z: M+ calcd for 
C11H10F5N2O2S = 329.0383, found: 329.0347.












5-Methyl-N-(4-(pentafluorothio)phenyl)isoxazole-4-carboxamide (87.4 mg, 0.27 
mmol) was dissolved in ethyl acetate (0.23 mL), mixed with 0.13 mL aqueous NaOH 
(15.20 mg, 0.38 mmol) and methanol (0.15 mL) and heated to 55°C for 1h. Then 
distilled water (0.39 mL) and 2N HCl solution (0.21 mL) was added at 30°C and the 
mixture stirred for 1 h at 30°C. The solvent was decanted, the product was washed 
three times with distilled water (9 mL) and dried in a high vacuum to yield a slightly 
pink amorphous solid (60.0 mg, 68%). 1H-NMR (600 MHz, DMSO-d6) δ = 11.19 (s, 
1H, H9), 10.16 (s, 1H, H9 (I)), 7.81 (d, J = 9.3 Hz, 2H, H12; H15), 7.75 (d, J = 9.1 Hz, 
2H, H11; H16), 2.38 (s, 1H, H8 (I)), 2.21 (s, 3H, H8). 13C-NMR (151 MHz, DMSO-d6) 
δ = 187.7 (s, C6), 166.8 (s, C2), 149.3 – 146.1 (m, 1C, C13), 142.4 (s, C10), 127.0 
(s, 2C, C12; C15), 120.4 (s, 2C, C11; C16), 120.2 (s, C4), 80.6 (s, C3), 24.5 (s, C8). 
19FNMR (282 MHz, DMSO-d6) δ = 166.4 (p, 2JFF = 152.5 Hz, 1F, F19), 142.5 (d, 
2JFF  = 151.0 Hz, 4F, F17; F18; F20; F21). LCMS (pos. ESI) m/z: [M+H]+ (calcd) for 
C11H10F5N2O2S = 329.0378; found: 329.1. HRMS (ESI) m/z: [M - H]- calcd for 
C11H9F5N2O2S = 328.0305, found: 328.0311.

































































































































H2O, 50°C, 20 min
NaHCO3,
H2O, 50°C, 20 min
Figure S1. Synthesis of leflunomide (B-D) and teriflunomide (E-G) derivatives. A. Synthesis of isoxazole acid chloride, B. Synthesis 
of CF3O-LF (4), C. Synthesis of di-CF3-LF (5), D. Synthesis of SF5-LF (6), E. Synthesis of CF3O-TF (1), F. Synthesis of di-CF3-TF 
(2), G. Synthesis of SF5-TF (3).
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Flow cytometry 
Figure S2. Flow cytometry analysis of proliferating cells. A. Selection of the 
lymphocyte population, B. Selection of single cells only, C. Selection of propidium 
iodide (PI) negative cells, while excluding death, thus stained cells, D. Gating for 
CFSE positive cells, showing 4 different subpopulations of cells with different 
proportions of CFSE positive cells; the bar divides non-proliferating cells from 
proliferating cells, E. Histogram of CFSE positive cells (treated with teriflunomide) 
and differentiation and quantification of non-proliferating (right hand side) from 
proliferating cells (left from the non-proliferating peak), F. Histogram of CFSE positive 
cells (without treatment but with proliferation stimulus; positive control), G. Histogram 
of CFSE positive cells (without treatment and without stimulus; negative control).
Enzyme inhibition and cell growth inhibition
Dose response model, including outlier detection and IC50 calculation for DHODH 
and CFSE data
The analysis of raw data from DHODH inhibition assays and CFSE cell proliferation 
assays was performed in R (version 3.6.1, R Foundation) using the drc R package for 
fitting a four-parameter logistic dose-response model to the data points 1, 2:
,𝑓(𝑥(𝑏,𝑐,𝑑,𝑒)) =  𝑐 +
𝑑 ― 𝑐
1 + exp(𝑏(𝑙𝑜𝑔(𝑥) ― 𝑙𝑜𝑔(𝑒))) 
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[b: steepness = Hill slope, c: upper limit, d: lower limit, e: halfway through 
point = point of inflection].
Outliers were detected and excluded from an initially robust fitting according to 
Motulsky and Brown 3 followed by a refitting of the data.
From the model, we calculated the drug concentration inhibiting 50 % (IC50) of either 
the enzymatic activity in DHODH inhibition assays or the proliferation of stimulated 
cells in CFSE cell proliferation assays for each compound (Figure S3). A 95 % 
confidence interval was calculated for each fit, indicating the concentration range 
which includes the IC50 with a probability of 95 %. 
Figure S3. Biological activity of teriflunomide (TF) derivatives. Dose response 
curves from DHODH (A-D) and cell proliferation assays (E-H) to assess the biological 
activity of teriflunomide derivatives. The reduction in activity in DHODH activity 
(duplicate measurements) and the proportion of proliferating cells in cell proliferation 
assays is depicted vs. increasing concentration of inhibitor. A dose-response model 
was fitted to the data points. Outliers were detected and excluded from the fitting 
(magenta). A 95% confidence interval is depicted in the plots. 
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Toxicology
Plate design and dilutions
For assessing the cytotoxicity of compounds, we performed a cytotoxicity test in 
HepG2 cells. Experiments were performed in 384 well plates (cellbind plate, Corning) 
in triplicates at seven concentrations ranging from 1.5 µM to 100 µM (DMSO 
concentration was 0.53 % in all wells). 5-FU (1 mM) was used as positive toxicity 
control and DMSO alone as negative control.
Cell culture
HepG2 cells were cultured in RPMI medium (10 % FCS) with 1800 cells per well. 
Compounds were added on the following day, and plates were incubated for 72 h. 
Assay
Following the incubation period, cells were fixed, stained, and measured using an 
automated widefield fluorescence microscope (Arrayscan XTI/Thermo). Hoechst 
3342 (Sigma Aldrich, final concentration 1 µM, nuclear staining) and Yo-Pro-1 
(Invitrogen, final concentration 0.1 µM, apoptosis assay) was used for live cell 
staining (1 h incubation). The live cell measurement microscopy was performed on 
two fluorescence channels at 20x magnification. The number of non-proliferating 
(Hoechst 3342+) and dead (Yo-Pro-1+) cells were quantified. Following fixation, viable 
cells were counted by microscopy, using 10x magnification. 
Comparison of growth inhibition and toxicology
We performed a growth inhibition assay and a cytotoxicity screening of TF and its 
derivatives in HepG2 cells to study their impact on liver cells as drug entrance and 
metabolic compartment. All compounds showed inhibitory activity in the 
concentration range of 1.5 µM to 100 µM. Cytotoxicity was assessed by quantifying 
damaged cells by apoptosis markers. TF did not show any cytotoxic effect in this 
concentration range compared to untreated negative controls. Equally, CF3O-TF did 
not display cytotoxic effects up to 100 µM. di-CF3-TF showed no cytotoxicity up to 
50 µM of concentration. SF5-TF showed minimal cytotoxic effects.
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Figure S4. Inhibitory activity and cytotoxicity of teriflunomide compounds in 
HepG2 cells. A-D. Cell growth inhibition of HepG2 cells at concentrations ranging 
from 1.5 to 100 µM, E-H. Surviving cells indicating cytotoxicity in HepG2 cells at 
concentrations ranging from 1.5 to 100 µM.
Additionally, we determined the cytotoxic effect of TF derivatives on PBMCs using a 
propidium iodide (PI) staining. In two patients and in comparison to untreated cells 
(both unstimulated and stimulated cells), the amount of surviving cells was above 
90 %.
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Figure S5. Cytotoxicity of teriflunomide compounds in PBMCs. Surviving cells in 
PBMCs at concentrations ranging from 0.39 to 50 µM, determined by propidium 
iodide (PI) staining after 72 h of incubation of cells with TF compounds. The 
experiment was performed in 2 individual patients, the orange line indicates the 
extent of at least 90 % of cell survival. 
MR characterization
Table S1. Concentrations of TF compounds in DMSO and serum phantoms
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Table S2. Full width half maximum (FWHM) of TF compounds in DMSO and serum





Table S3. Optimized sequence parameters for SNR efficiency measurements  
Compound TF CF3O-TF di-CF3-TF SF5-TF
Medium (RT) DMSO Serum DMSO Serum DMSO Serum DMSO Serum
TR for RARE (ms) 1968 1305 3610 1026 1943 1130 596 389
ETL for RARE 48 8 96 16 48 8 8 4
bSSFP flip angle (°) 71 8 74 12 75 9 46 15
Ernst angle (°) 25 25 20 19 24 27 40 42
19F MR Images of the DMSO and serum phantoms
Figure S6. 19F MR Images of phantoms containing TF compounds dissolved in 
DMSO and in serum. Optimized scan parameters were used and the SNR efficiency 
normalized to the concentrations in the phantoms was compared.
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19F MR spectral line splitting of SF5-TF in DMSO
Figure S7. 19F MR spectroscopy of a phantom containing TF dissolved in DMSO. 
The doublet at 67.4 ppm is shown separately from the pentet at 91.7 ppm.
Biological and 19F MR reporter activity of TF and SF5-TF
We administered TF and SF5-TF orally to C57BL/6 mice (n = 6) using the same 
molar concentrations: TF =12.15 mg/ml (n = 3) and SF5-TF = 10 mg/ml (n = 3). 19F 
MR UTE MR images were then acquired using optimized parameters. Peak 19F SNR 
values for each compound were calculated for all 6 mouse stomachs (Table S4). 
These values were calculated from the 19F MR images of TF and SF5-TF (Figure 
S8). 
Table S4. Peak SNR values for 19F MR UTE MR images of TF and SF5-TF
Mouse Compound Figure Peak SNR
1 TF S8A 6.8492
2 TF S8B 8.0581
3 TF S8C 2.5269
4 SF5-TF S8D 14.4034
5 SF5-TF S8E 12.0337
6 SF5-TF S8F 13.197
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Figure S8. 19F MR reporter activity of TF (A-C) and SF5-TF (D-F) in the stomach of 
C57BL/6 mice ex vivo. All 1H RARE anatomical images: TR = 2 s, TE = 10 ms, 
TA = 1 min, 4 s. 19F UTE MRI of TF: TR = 100 ms, TE = 0.27 ms, FA = 25 °. 19F UTE 
MRI of SF5-TF: TR = 100 ms, TE = 0.27 ms, FA = 42 °. All acquisition times (TA) for 
19F UTE MRI were 2 h, 30 min, except for the third TF-treated stomach (C). Due to 
the low signal-to-noise ratio (SNR) for this sample (C) we used a TA = 12 h, 30 min 
(5x longer acquisition time) and SNR was then downscaled by √5 and this value 
indicated in Table S4. SNR is indicated by the color bars.
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